Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

CSI 300 June 2026 Rebalance: Post-Implementation Review

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

China Tungsten And Hightech Ma / Index Rebalance

China Tungsten And Hightech Ma (000657 CH)

<ul>
<li>CSI confirmed 19 ADDs and 19 DELETEs for the June 2026 rebalance, effective 15 Jun 2026.</li>
<li>ADD gains narrowed to seven positive-bridge names, led by Xiamen Tungsten and China Tungsten. DELETEs fell -4.4% on average.</li>
<li>Historical first-week outcomes were negative on average for both ADD and DELETE, but different subgroup recorded varied performance.</li>
</ul>


CSI confirmed 19 ADDs and 19 DELETEs for the June 2026 rebalance, effective 15 Jun 2026.
ADD gains narrowed to seven positive-bridge names, led by Xiamen Tungsten and China Tungsten. DELETEs fell -4.4% on average.
Historical first-week outcomes were negative on average for both ADD and DELETE, but different subgroup recorded varied performance.


Shanghai Electric Group Company (601727 CH)

Hangzhou Tigermed Consulting (A) (300347 CH)

Xinjiang Goldwind Science & Technology (002202 CH)

Beijing Tiantan Biological Products (600161 CH)

Beijing New Building Materials (000786 CH)

Wuxi Lead Intelligent Equipmen (300450 CH)

Shanghai RAAS Blood Products C (002252 CH)

Verisilicon Microelectronics S (688521 CH)

CSI 300 June 2026 Rebalance: Pre-Implementation Update